Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Histone demethylases and their roles in cancer epigenetics.

D'Oto A, Tian QW, Davidoff AM, Yang J.

J Med Oncol Ther. 2016;1(2):34-40.

2.

SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer.

Mukherjee N, Cardenas E, Bedolla R, Ghosh R.

Oncotarget. 2017 Feb 28;8(9):15114-15125. doi: 10.18632/oncotarget.14750.

3.

KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.

Castellini L, Moon EJ, Razorenova OV, Krieg AJ, von Eyben R, Giaccia AJ.

Nucleic Acids Res. 2017 Apr 20;45(7):3674-3692. doi: 10.1093/nar/gkw1281.

4.

Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma.

Zhu F, Hwang B, Miyamoto S, Rui L.

Mol Cancer Res. 2017 Mar;15(3):348-357. doi: 10.1158/1541-7786.MCR-16-0344. Epub 2016 Dec 28.

5.

KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.

Garcia J, Lizcano F.

Breast Cancer (Auckl). 2016 Nov 2;10:169-175. eCollection 2016.

6.

Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.

Rui L, Drennan AC, Ceribelli M, Zhu F, Wright GW, Huang DW, Xiao W, Li Y, Grindle KM, Lu L, Hodson DJ, Shaffer AL, Zhao H, Xu W, Yang Y, Staudt LM.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7260-E7267. Epub 2016 Oct 31.

7.

KDM4C, a H3K9me3 Histone Demethylase, is Involved in the Maintenance of Human ESCC-Initiating Cells by Epigenetically Enhancing SOX2 Expression.

Yuan X, Kong J, Ma Z, Li N, Jia R, Liu Y, Zhou F, Zhan Q, Liu G, Gao S.

Neoplasia. 2016 Oct;18(10):594-609. doi: 10.1016/j.neo.2016.08.005. Epub 2016 Sep 19.

8.

Maybe we don't know JAK?

Schwarz LJ, Balko JM.

Mol Cell Oncol. 2016 May 31;3(4):e1192713. doi: 10.1080/23723556.2016.1192713. eCollection 2016 Jul.

9.

DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics.

Bhattacharjee D, Shenoy S, Bairy KL.

Scientifica (Cairo). 2016;2016:6072357. doi: 10.1155/2016/6072357. Epub 2016 Mar 28. Review.

10.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL.

Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001.

11.

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.

Ju W, Zhang M, Wilson KM, Petrus MN, Bamford RN, Zhang X, Guha R, Ferrer M, Thomas CJ, Waldmann TA.

Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1624-9. doi: 10.1073/pnas.1524668113. Epub 2016 Jan 25.

12.

Integration of Signaling Pathways with the Epigenetic Machinery in the Maintenance of Stem Cells.

Fagnocchi L, Mazzoleni S, Zippo A.

Stem Cells Int. 2016;2016:8652748. doi: 10.1155/2016/8652748. Epub 2015 Dec 20. Review.

13.

KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism.

Zhao E, Ding J, Xia Y, Liu M, Ye B, Choi JH, Yan C, Dong Z, Huang S, Zha Y, Yang L, Cui H, Ding HF.

Cell Rep. 2016 Jan 26;14(3):506-19. doi: 10.1016/j.celrep.2015.12.053. Epub 2016 Jan 7.

14.

Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.

Cheung N, Fung TK, Zeisig BB, Holmes K, Rane JK, Mowen KA, Finn MG, Lenhard B, Chan LC, So CW.

Cancer Cell. 2016 Jan 11;29(1):32-48. doi: 10.1016/j.ccell.2015.12.007.

15.

Targetable genetic features of primary testicular and primary central nervous system lymphomas.

Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA.

Blood. 2016 Feb 18;127(7):869-81. doi: 10.1182/blood-2015-10-673236. Epub 2015 Dec 23.

16.

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Camicia R, Winkler HC, Hassa PO.

Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2. Review.

17.

Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.

Liu H, Liu L, Holowatyj A, Jiang Y, Yang ZQ.

Mol Carcinog. 2016 May;55(5):977-90. doi: 10.1002/mc.22341. Epub 2015 Jul 24.

18.

Potential role of hypoxia in early stages of Hodgkin lymphoma pathogenesis.

Wein F, Otto T, Lambertz P, Fandrey J, Hansmann ML, Küppers R.

Haematologica. 2015 Oct;100(10):1320-6. doi: 10.3324/haematol.2015.127498. Epub 2015 Jul 9.

19.

Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.

Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T, Yang ZQ.

Am J Cancer Res. 2015 Mar 15;5(4):1519-30. eCollection 2015.

20.

SEPTIN2 and STATHMIN Regulate CD99-Mediated Cellular Differentiation in Hodgkin's Lymphoma.

Jian W, Zhong L, Wen J, Tang Y, Qiu B, Wu Z, Yan J, Zhou X, Zhao T.

PLoS One. 2015 May 22;10(5):e0127568. doi: 10.1371/journal.pone.0127568. eCollection 2015.

Supplemental Content

Support Center